Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 6, 2007, Pages

  Isbell, David C ^a   Voros, Szilard ^a   Yang, Zequan ^a   DiMaria, Joseph M ^a   Berr, Stuart S ^a   French, Brent A ^a   Epstein, Frederick H ^a   Bishop, Sanford P ^b   Wang, Hongkun ^a   Roy, Rene J ^a   Kemp, Brandon A ^a   Matsubara, Hiroaki ^c   Carey, Robert M ^a   Kramer, Christopher M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b University of Alabama at Birmingham   (United States)

^c KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Magnetic resonance imaging; Remodeling

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BRADYKININ B2 RECEPTOR; COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART EJECTION FRACTION; HEART INFARCTION; HYPERTROPHY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; TRANSGENIC MOUSE;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CELL SIZE; COLLAGEN; DISEASE MODELS, ANIMAL; HEART RATE; MAGNETIC RESONANCE IMAGING, CINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; STROKE VOLUME; TIME FACTORS; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 36849028767     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00997.2007     Document Type: Article

References (48)

1. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42: 600-604, 2003.
2. Baxter GF, Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol 135: 843-854, 2002.
3. Bouchard JF, Chouinard J, Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br J Pharmacol 123: 413-420, 1998.
4. Bove CM, Yang Z, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Matsubara H, Carey RM, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension 43: 680-685, 2004.
5. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 103: 904-912, 2001.
6. 2 receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 157: 605-611, 2000.
7. 2) angiotensin receptor. Acta Physiol Scand 168: 65-71, 2000.
8. 1 bradykinin receptor in normotension and hypertension. Circ Res 88: 275-281, 2001.
9. 2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development. Physiol Genomics 3: 121-131, 2000.
10. 1 receptor for therapeutic neovascularization. Circulation 105: 360-366, 2002.
11. 2 receptor knockout mice. Circulation 100: 2359-2365, 1999.
12. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 32: 84-88, 1998.
13. Gardiner SM, Kemp PA, Bennett T, Bose C, Foulkes R, Hughes B. Involvement of beta 2-adrenoceptors in the regional haemodynamic responses to bradykinin in conscious rats. Br J Pharmacol 105: 839-848, 1992.
14. Gavras I, Gavras H. Hypertension, vasoactive peptides and coagulation factors. J Hypertens 22: 1091-1092, 2004.
15. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355, 1998.
16. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19: 1172-1174, 2005.
17. Hatta E, Rubin LE, Seyedi N, Levi R. Bradykinin and cardioprotection: don't set your heart on it. Pharmacol Res 35: 531-536, 1997.
18. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 106: 2244-2249, 2002.
19. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol Heart Circ Physiol 272: H722-H727, 1997.
20. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
21. Liu YH, Yang XP, Shesely EG, Sankey SS, Carretero OA. Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol 43: 1473-1480, 2004.
22. 2 receptor knockout mice. Hypertension 35: 391-396, 2000.
23. Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M, Corradi D, Emanueli C, Madeddu P. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41: 1151-1155, 2003.
24. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 50: 357-386, 1998.
25. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101: 527-535, 1998.
26. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182-1191, 1998.
27. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110: 3281-3288, 2004.
28. Meyer M, Bluhm WF, He H, Post SR, Giordano FJ, Lew WY, Dillmann WH. Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am J Physiol Heart Circ Physiol 276: H779-H785, 1999.
29. Nagamatsu S, Kornhauser JM, Burant CF, Seino S, Mayo KE, Bell GI. Glucose transporter expression in brain. cDNA sequence of mouse GLUT3, the brain facilitative glucose transporter isoform, and identification of sites of expression by in situ hybridization. J Biol Chem 267: 467-472, 1992.
30. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319: 80-86, 1988.
31. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906, 2003.
32. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15: 79-87, 2001.
33. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 31: 39-44, 1998.
34. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423, 1993.
35. Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 49: 155-161, 2007.
36. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33: 1237-1242, 1999.
37. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 35: 1074-1077, 2000.
38. Siragy HM, de Gasparo M, El Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38: 183-186, 2001.
39. Trabold F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, Richer-Giudicelli C, Meneton P. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40: 90-95, 2002.
40. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104: 925-935, 1999.
41. 2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol 290: H1004-H1010, 2006.
42. Wang Q, Hummler E, Nussberger J, Clement S, Gabbiani G, Brunner HR, Burnier M. Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. J Am Soc Nephrol 13: 1509-1516, 2002.
43. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 140: 809-824, 2003.
44. 2 kinin receptor gene knockout mice. Circ Res 88: 1072-1079, 2001.
45. Yang Z, Berr SS, Gilson WD, Toufektsian MC, French BA. Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction. Circulation 109: 1161-1167, 2004.
46. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, Gibson JJ, Carey RM, Kramer CM. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 106: 106-111, 2002.
47. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 101: 1019-1026, 2000.
48. Zhao Y, Biermann T, Luther C, Unger T, Culman J, Gohlke P. Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem 85: 759-767, 2003.